Revascor mesenchymal precursor cells: Phase II ongoing

Angioblast will begin enrolling a second cohort of 20 patients in a Phase II trial (HF-AB002) of Revascor after a DSMB found no cell-related adverse events during a 30-day follow-up of patients enroll...